Electrocardiographic Changes Associated With Ibrutinib Exposure
Although ibrutinib-associated atrial and ventricular arrhythmias have been well described, there is little information about ibrutinib’s effects on other electrocardiographic parameters, particularly the QT interval. Using our database of 137 patients treated with ibrutinib, we retrospectively ident...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-06-01
|
| Series: | Cancer Control |
| Online Access: | https://doi.org/10.1177/1073274820931808 |
| _version_ | 1827893075927629824 |
|---|---|
| author | Michael G. Fradley MD Allan Welter-Frost MD Matthew Gliksman BS Josephine Emole MD Federico Viganego MD Dae Hyun Lee MD Bijal Shah MD Julio C. Chavez MD Javier Pinilla-Ibarz MD, PhD Matthew B. Schabath PhD |
| author_facet | Michael G. Fradley MD Allan Welter-Frost MD Matthew Gliksman BS Josephine Emole MD Federico Viganego MD Dae Hyun Lee MD Bijal Shah MD Julio C. Chavez MD Javier Pinilla-Ibarz MD, PhD Matthew B. Schabath PhD |
| author_sort | Michael G. Fradley MD |
| collection | DOAJ |
| description | Although ibrutinib-associated atrial and ventricular arrhythmias have been well described, there is little information about ibrutinib’s effects on other electrocardiographic parameters, particularly the QT interval. Using our database of 137 patients treated with ibrutinib, we retrospectively identified 21 patients in whom an electrocardiogram (ECG) was obtained both prior to and after ibrutinib exposure. All traditional ECG parameters as well as QT dispersion were manually measured by an electrophysiologist. Compared to baseline ECGs, post ibrutinib ECGs demonstrated QT interval shortening from 386 ms to 356 ms ( P = .007), corrected QT interval shortening using Bazett’s formula from 446 ms to 437 ms ( P = .04), and corrected QT interval shortening using Fridericia’s formula from 425 ms to 407 ms ( P = .003). QT dispersion also increased post ibrutinib exposure compared to baseline (39.8 ms vs 57.3 ms, P = .002). There was no significant change in other ECG parameters. In conclusion, both the absolute and corrected QT intervals significantly shortened after ibrutinib exposure, while there was a significant increase in QT dispersion. These findings may point to a common underlying electrophysiologic mechanism of ibrutinib-associated arrhythmias. |
| first_indexed | 2024-03-12T21:48:49Z |
| format | Article |
| id | doaj.art-005962e3eea74a9f9667942bc5009943 |
| institution | Directory Open Access Journal |
| issn | 1073-2748 |
| language | English |
| last_indexed | 2024-03-12T21:48:49Z |
| publishDate | 2020-06-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cancer Control |
| spelling | doaj.art-005962e3eea74a9f9667942bc50099432023-07-26T06:35:25ZengSAGE PublishingCancer Control1073-27482020-06-012710.1177/1073274820931808Electrocardiographic Changes Associated With Ibrutinib ExposureMichael G. Fradley MD0Allan Welter-Frost MD1Matthew Gliksman BS2Josephine Emole MD3Federico Viganego MD4Dae Hyun Lee MD5Bijal Shah MD6Julio C. Chavez MD7Javier Pinilla-Ibarz MD, PhD8Matthew B. Schabath PhD9 Cardio-Oncology Program, Division of Cardiovascular Medicine, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine, Tampa, FL, USA Cardio-Oncology Program, Division of Cardiovascular Medicine, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine, Tampa, FL, USA Cardio-Oncology Program, Division of Cardiovascular Medicine, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine, Tampa, FL, USA Department of Medical Oncology, Henry Ford Health System, Detroit MI, USA Cardio-Oncology Program, Division of Cardiovascular Medicine, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine, Tampa, FL, USA Cardio-Oncology Program, Division of Cardiovascular Medicine, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine, Tampa, FL, USA Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAAlthough ibrutinib-associated atrial and ventricular arrhythmias have been well described, there is little information about ibrutinib’s effects on other electrocardiographic parameters, particularly the QT interval. Using our database of 137 patients treated with ibrutinib, we retrospectively identified 21 patients in whom an electrocardiogram (ECG) was obtained both prior to and after ibrutinib exposure. All traditional ECG parameters as well as QT dispersion were manually measured by an electrophysiologist. Compared to baseline ECGs, post ibrutinib ECGs demonstrated QT interval shortening from 386 ms to 356 ms ( P = .007), corrected QT interval shortening using Bazett’s formula from 446 ms to 437 ms ( P = .04), and corrected QT interval shortening using Fridericia’s formula from 425 ms to 407 ms ( P = .003). QT dispersion also increased post ibrutinib exposure compared to baseline (39.8 ms vs 57.3 ms, P = .002). There was no significant change in other ECG parameters. In conclusion, both the absolute and corrected QT intervals significantly shortened after ibrutinib exposure, while there was a significant increase in QT dispersion. These findings may point to a common underlying electrophysiologic mechanism of ibrutinib-associated arrhythmias.https://doi.org/10.1177/1073274820931808 |
| spellingShingle | Michael G. Fradley MD Allan Welter-Frost MD Matthew Gliksman BS Josephine Emole MD Federico Viganego MD Dae Hyun Lee MD Bijal Shah MD Julio C. Chavez MD Javier Pinilla-Ibarz MD, PhD Matthew B. Schabath PhD Electrocardiographic Changes Associated With Ibrutinib Exposure Cancer Control |
| title | Electrocardiographic Changes Associated With Ibrutinib Exposure |
| title_full | Electrocardiographic Changes Associated With Ibrutinib Exposure |
| title_fullStr | Electrocardiographic Changes Associated With Ibrutinib Exposure |
| title_full_unstemmed | Electrocardiographic Changes Associated With Ibrutinib Exposure |
| title_short | Electrocardiographic Changes Associated With Ibrutinib Exposure |
| title_sort | electrocardiographic changes associated with ibrutinib exposure |
| url | https://doi.org/10.1177/1073274820931808 |
| work_keys_str_mv | AT michaelgfradleymd electrocardiographicchangesassociatedwithibrutinibexposure AT allanwelterfrostmd electrocardiographicchangesassociatedwithibrutinibexposure AT matthewgliksmanbs electrocardiographicchangesassociatedwithibrutinibexposure AT josephineemolemd electrocardiographicchangesassociatedwithibrutinibexposure AT federicoviganegomd electrocardiographicchangesassociatedwithibrutinibexposure AT daehyunleemd electrocardiographicchangesassociatedwithibrutinibexposure AT bijalshahmd electrocardiographicchangesassociatedwithibrutinibexposure AT juliocchavezmd electrocardiographicchangesassociatedwithibrutinibexposure AT javierpinillaibarzmdphd electrocardiographicchangesassociatedwithibrutinibexposure AT matthewbschabathphd electrocardiographicchangesassociatedwithibrutinibexposure |